Q4 2024 Tactile Systems Technology Inc Earnings Call Transcript
Key Points
- Tactile Systems Technology Inc (TCMD) reported a strong Q4 performance with total revenue of $85.6 million, marking a 10.2% year-over-year growth.
- The lymphedema business line saw a significant sales increase of 11% year over year, with a sequential growth of 18.1%.
- Gross margins improved by 310 basis points year over year, reflecting better manufacturing and warranty cost management.
- The company successfully launched Nimbl, a next-generation lymphedema PCD offering, which has been well-received by clinicians and patients.
- Cash and cash equivalents increased by $12.2 million sequentially, enhancing the company's financial position with a year-end cash balance of $94.4 million.
- The company faced challenges with changes in the Medicare policy environment, which created headwinds throughout the year.
- Operating expenses increased by 17.3% to $51.9 million, driven by strategic technology investments and increased sales and marketing expenses.
- The increased documentation requirements by MACs under the LCD policy created administrative burdens and potential patient leakage.
- Despite the positive revenue growth, the adjusted EBITDA guidance for 2025 is flat to down $2 million, indicating increased investment costs.
- The company is still navigating the ongoing legal matter related to qui tam, with uncertainty about government intervention.
Please stand by. Welcome, ladies and gentlemen, to the fourth quarter and fiscal year 2024 earnings conference call for Tactile Medical. (Operator Instructions) Please note that this conference call is being recorded and will be available on the company's website for replay shortly.
I would now like to turn the call over to Sam Bentzinger, Investor Relations at Gilmartin Group, for a few introductory comments. Please go ahead.
Good afternoon, and thank you for joining the call today. With me from Tactile's management team are Sheri Dodd, Chief Executive Officer; and Elaine Birkemeyer, Chief Financial Officer.
Before we begin, I'd like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties. These could cause actual results to differ materially from those indicated, including those identified in the Risk Factors section of our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
